For your patients with Homozygous FH (HoFH)1
EVKEEZA is an ANGPTL3 (angiopoietin-like 3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL‑C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia.
Limitations of Use:
- The safety and effectiveness of EVKEEZA have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH)
- The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined
HoFH is an ultra-rare, life-threatening disorder of lipid metabolism.2
References: 1. EVKEEZA Prescribing Information. Tarrytown, NY: Regeneron Pharmaceuticals; 2021. 2. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146-2157.